Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Study in healthy volunteers of the safety and how the body handles PCN-101


To see complete record on anzctr.org.au, please visit this link

Id: ACTRN12620000226909

Organisation Name: PERCEPTION NEUROSCIENCE, INC.

Overal Status: Not yet recruiting

Start Date: 03/03/2020

Brief Summary: This study in healthy volunteers aims to identify safe single doses of PCN-101 administered IV; to assess how the body handles IV PCN-101; and to compare the safety of PCN-101 and esketamine. The study aims to identify tolerable dosing of IV PCN-101 to be evaluated in future clinical trials. Part 1 of the study is an ascending dose, double-blind safety and tolerability study of single doses of IV PCN-101. Up to 48 healthy volunteers will be enrolled to receive a single dose of PCN-101 or placebo, as an infusion over 40 minutes. Part 2 is a double-blind, cross-over safety and tolerability study comparing a single dose of PCN-101 versus esketamine, both given IV over 40 minutes. Ten healthy volunteers will be randomized into one of two treatment groups. Group 1 will receive a single infusion of PCN-101 and then an infusion of esketamine. In Group 2, the order of infusions will be reversed. Safety will be assessed via vital signs, 12-lead ECG, clinical laboratory tests, neuropsychological scales, sedation and adverse events.

Countries:
  • New Zealand
  • Auckland
  • United States of America


Total execution time in seconds: 0.084649085998535